Skip to main content

Table 1 Baseline characteristics of participants enrolled and completing follow-up (n = 421)

From: Efficacy and safety of artesunate–amodiaquine and artemether–lumefantrine and prevalence of molecular markers associated with resistance, Guinea: an open-label two-arm randomised controlled trial

Variables

Maferinyah (n = 211)

Labé (n = 210)

ASAQ

AL

ASAQ

AL

Participant characteristics at baseline

 Median age, in month (interquartile range)

36 (24–48)

36 (24–59)

45 (24–59)

36 (24–48)

 Median weight, kg (interquartile range)

14 (10–16)

13 (11–16)

13 (10–16)

13 (10–15)

 Percent female, n (%)

55 (51.4)

39 (37.5)

40 (38.1)

43 (41.0)

 Median day 0 parasitemia, parasites/µl * 103 (interquartile range)

19.4 (101–519)

27.4 (10.2–55.0)

30.2 (13.0–63.9)

30,450 (13.1–49.6)

 Median day 0 haemoglobin, g/dl (interquartile range)

9.7 (8–10)

9.8 (8–10)

10.7 (9–11)

10.6 (8.5–11)

  1. AL artemether–lumefantrine, ASAQ artesunate–amodiaquine